

P.O. Box 946 / Montgomery, AL 36101-0946 / (334) 242-4116 Under Alabama Law, this document is a public record and will be provided upon request

### **Quality Assurance Plan for Controlled Prescribing**

PP and Certification:			AL License #:	
Collaborating/ Supervising Physician Name	2:			
Specialty of Collaborating/Supervising Phy	sician:			
management with defined quality outcome Advanced Practice Provider and include a r	measures for evalueview of a meaning not limited to, el records that were	luation of the pre ngful sample of ectronic medical	medical records plus all adverse outcomes. l records. Documentation of quality assurance	
Patient Group:	Sample Size	Review	<b>Designated Personnel</b> (Individual who will compile data)	
Patients Receiving Controlled Substances	10%	Quarterly		
			*Provide who will compile data	
Adverse Outcomes	100 %	Immediately	Physician and APP	
<ol> <li>Summary of the quality assurance finding</li> <li>Recommendations for change, if indicate</li> <li>Summary Statement</li> <li>Adverse Outcome Report</li> <li>Date of review, and signature of APP and</li> </ol>	d		APP and collaborating/ supervising physician	
The completed quality assurance reviews	are to remain o	n file at the pra	actice site.	
	8-1A-2 and 8-1A	-7. I attest that th	signature that has the same legal effect as a he foregoing information has been provided belief.	
Print Name of Physician Sig	gnature of Physic	ian	Date	
Print Name of APP Sig	gnature of APP		Date	

Revised 7/2025 Page 1 of 5



P.O. Box 946 / Montgomery, AL 36101-0946 / (334) 242-4116 Under Alabama Law, this document is a public record and will be provided upon request

### **COLLECTIVE QA REPORT: PRESCRIBED MEDICATIONS**

Required Quarterly Review:	Q1 Q2	Q3 Q4	Date of Review:	
Total # of Patients Seen:		Adverse Ou	tcomes: Yes No	
			of charts, with identifiers listed be ewed for the following prescribed	

- 1. Medications are prescribed per FDA guidelines (per PDR or Product Insert)
- 2. Proper chart documentation of medication name, dosage, and directions for use are present and legible
- 3. Medications prescribed are appropriate for the patient diagnosis according to practice protocol
- 4. Controlled medications were ordered according to regulations of the BME
- 5. When the PDMP was reviewed, were there any concerning prescribing patterns?
- 6. Has the physician physically seen the patient as required by the QACSC/LPSP protocols?
- 7. Was the physician's medical decision-making, evaluation, and consultation regarding the continuation or escalation of therapy appropriately documented in the medical record?
- 8. Were Risk Mitigation Strategies utilized and documented?
- 9. The patient's risk for substance abuse and addiction must be evaluated using the Screening to Brief Intervention (S2BI) tool. Was this completed?
- 10. If positive, were the results reviewed with the physician and documented in the patient's chart prior to initiating the prescription or therapy?

Chart #/ Identifier			
Date of Service			
<b>D=Discussed</b> –noted	1.	1.	1.
changes needed	2.	2.	2.
= Appropriate	3.	3.	3.
NA=Not applicable	4.	4.	4.
	5.	5.	5.
	6.	6.	6.
	7.	7.	7.
	8.	8.	8.
	9.	9.	9.
	10.	10.	10.

Revised 8/2025 Page 2 of 5

Chart #/ Identifier			
Date of Service			
<b>D=Discussed</b> –noted	1.	1.	1.
changes needed	2.	2.	2.
= Appropriate	3.	3.	3.
NA=Not applicable	4.	4.	4.
	5.	5.	5.
	6.	6.	6.
	7.	7.	7.
	8.	8.	8.
	9.	9.	9.
	10.	10.	10.

Chart #/ Identifier			
Date of Service			
<b>D</b> =Discussed –noted	1.	1.	1.
changes needed	2.	2.	2.
= Appropriate	3.	3.	3.
NA=Not applicable	4.	4.	4.
	5.	5.	5.
	6.	6.	6.
	7.	7.	7.
	8.	8.	8.
	9.	9.	9.
	10.	10.	10.

Chart #/ Identifier			
Date of Service			
<b>D</b> = Discussed-noted	1.	1.	1.
changes needed	2.	2.	2.
$\sqrt{=}$ Appropriate	3.	3.	3.
<b>NA</b> = Not applicable	4.	4.	4.
	5.	5.	5.
	6.	6.	6.
	7.	7.	7.
	8.	8.	8.
	9.	9.	9.
	10.	10.	10.

Physician has reviewed /discussed all the above with APP. All adverse events have been reviewed and *noted with the letter A*.

Physician Signature:	Date:
APP Signature:	Date:

Revised 8/2025 Page 3 of 5



P.O. Box 946 / Montgomery, AL 36101-0946 / (334) 242-4116 Under Alabama Law, this document is a public record and will be provided upon request

# **SUMMARY OF FINDINGS Controlled Prescribing QA**

Quarter (1, 2, 3, 4):	Date Reviewed:
Number of Charts Audited:	
Summary of Findings:	
No specific prescribing issues identified	
Certain prescribing issues are in question (se	ee comments)
Adverse Event findings identified (see Adve	erse Event Review/Report)
PDMP Reviewed/ Discrepancies Reported (	Optional My Rx Report reviewed)
Comments/Discussions/Changes to be made (if any	y):
Physician Name/Signature:	Date:
APP Name/Signature:	Date:

Revised 7/2025 Page 4 of 5



P.O. Box 946 / Montgomery, AL 36101-0946 / (334) 242-4116 Under Alabama Law, this document is a public record and will be provided upon request

#### ADVERSE EVENT REVIEW/ REPORT

Office Name:	
Address:	
Phone Number:	
Patient Identifier:	DOB:
Physician Name:	License Number
APP Name:	License Number:
Date of Adverse Event:	Patient Age/ Gender:
Indicate the Adverse Event:	
Patient Hospitalized: Yes No	
Patient Outcome: Full Recovery Disability	ry Death Pending
Provide a brief narrative description of the adver	rse event and include any recommendations for change:
Signature of APP:	Date:

Revised 7/2025 Page 5 of 5